Jim Simons
SNDX icon

Jim Simons’s Syndax Pharmaceuticals SNDX Stock Holding History

Jim Simons’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Sell
498,200
-46,600
-9% -$1.01M 0.02% 897
2025
Q4 		$11.4M Sell
544,800
-315,700
-37% -$5.51M 0.02% 853
2025
Q3 		$13.2M Buy
860,500
+22,800
+3% +$298K 0.02% 939
2025
Q2 		$7.85M Buy
837,700
+156,273
+23% +$1.72M 0.01% 1228
2025
Q1 		$8.37M Buy
681,427
+462
+0.1% +$6.52K 0.01% 1104
2024
Q4 		$9M Buy
+680,965
New +$11.7M 0.01% 1082
2024
Q3 		– Sell
-214,300
Closed -$4.4M – 3854
2024
Q2 		$4.4M Buy
214,300
+135,200
+171% +$2.83M 0.01% 1390
2024
Q1 		$1.88M Buy
+79,100
New +$1.76M ﹤0.01% 2071
2023
Q4 		– Sell
-218,300
Closed -$3.17M – 4100
2023
Q3 		$3.17M Buy
+218,300
New +$4.13M 0.01% 1570
2023
Q1 		– Sell
-81,200
Closed -$2.07M – 4357
2022
Q4 		$2.07M Buy
+81,200
New +$1.89M ﹤0.01% 2046
2022
Q2 		– Sell
-182,100
Closed -$3.17M – 4548
2022
Q1 		$3.17M Buy
+182,100
New +$3.07M ﹤0.01% 1884
2020
Q3 		– Sell
-94,700
Closed -$1.4M – 3661
2020
Q2 		$1.4M Sell
94,700
-392,900
-81% -$5.98M ﹤0.01% 2373
2020
Q1 		$5.35M Sell
487,600
-7,900
-2% -$74.1K 0.01% 1520
2019
Q4 		$4.35M Sell
495,500
-1,500
-0.3% -$11K ﹤0.01% 1940
2019
Q3 		$3.71M Buy
497,000
+65,100
+15% +$593K ﹤0.01% 1961
2019
Q2 		$4.02M Buy
431,900
+117,300
+37% +$855K ﹤0.01% 1932
2019
Q1 		$1.65M Buy
314,600
+85,500
+37% +$488K ﹤0.01% 2412
2018
Q4 		$1.02M Sell
229,100
-50,200
-18% -$275K ﹤0.01% 2561
2018
Q3 		$2.26M Buy
279,300
+237,000
+560% +$1.69M ﹤0.01% 2214
2018
Q2 		$297K Sell
42,300
-10,200
-19% -$100K ﹤0.01% 2965
2018
Q1 		$747K Buy
52,500
+26,800
+104% +$284K ﹤0.01% 2778
2017
Q4 		$225K Buy
+25,700
New +$254K ﹤0.01% 3102

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Jim Simons's SNDX Position: Q1 2026 in Review

Jim Simons reduced its Syndax Pharmaceuticals (SNDX) stake by 8.6% in Q1 2026, selling an estimated $1.01M and leaving 498,200 shares worth $11.6M. The position accounts for 0.02% of the portfolio, ranked #897.

Jim Simons first reported a position in SNDX in Q4 2017 and has held it in 22 quarters since. The position peaked at $13.2M in Q3 2025. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Jim Simons held 498,200 shares of Syndax Pharmaceuticals worth $11.6M as of Q1 2026.
  • Jim Simons sold 46,600 Syndax Pharmaceuticals shares in Q1 2026, an estimated $1.01M.
  • Syndax Pharmaceuticals made up 0.02% of Jim Simons's portfolio in Q1 2026, its #897 holding.
  • Jim Simons first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 22 quarters since.
  • Jim Simons's Syndax Pharmaceuticals position peaked at $13.2M in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.